Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sawai's Upsher-Smith Snaps Up Dr Reddy’s Branded Migraine Assets

Executive Summary

Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.

You may also be interested in...

Japan’s Sawai Forecasts Sales Milestone This Year

Sales growth through new product launches and increasing the value of its current portfolio will allow Sawai to increase sales by around a tenth this year, the Japanese firm has forecasted, as it also revealed full-year financials for the 12 months ended 31 March 2020.

Upsher-Smith Completes Acquisition Of Dr Reddy’s Two Migraine Treatments

Upsher-Smith strategically expands and diversifies its portfolio by acquiring Dr Reddy’s two treatments of acute migraine in adults.

Product Delays Dull Dr Reddy’s Despite Upbeat Management

Dr Reddy’s had a generally positive Q4 but a slow ramp in some products in the US and potential delays in anticipated launches there are among the challenges that appear to have jaded investor outlook. Management commentary, though, was optimistic, with around 30 launches lined up for the US, a China/India thrust and M&A staying an important cog for growth.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts